Eric Bouffet

Jan 31, 2024 | tandfonline.com | Eric Bouffet

References Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: Current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017 Jul 20;35(21):2370–2377. doi: 10.1200/JCO.2017.73.0242 View PubMed Web of Science ®Google Scholar de Blank P, Bandopadhayay P, Haas-Kogan D, et al. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019 Feb;31(1):21–27. doi: 10.1097/MOP.0000000000000717 View PubMed Web of Science ®Google Scholar Fried I, Tabori U, Tihan T, et al.

Sep 20, 2023 | nejm.org | Eric Bouffet |Jordan Hansford |Maria Luisa Garrè |Ashley Plant-Fox

September 21, 2023N Engl J Med 2023; 389:1108-1120 DOI: 10.1056/NEJMoa2303815 AbstractDetection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with BRAF V600 mutations, findings that warrant further evaluation of this combination as first-line therapy.